Andexanet alfa for reversal of rivaroxaban in a child with intracranial hemorrhage
Open Access
- 22 November 2021
- journal article
- letter
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (6) , e29484
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trialThe Lancet Haematology, 2021
- Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT)Blood Advances, 2020
- Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE)Blood Advances, 2020
- Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trialThe Lancet Haematology, 2020
- A multi-national trial of a direct oral anticoagulant in children with cardiac disease: Design and rationale of the Safety of ApiXaban On Pediatric Heart disease On the preventioN of Embolism (SAXOPHONE) studyAmerican Heart Journal, 2019
- Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa InhibitorsNew England Journal of Medicine, 2019
- PREVAPIX-ALL: Apixaban Compared to Standard of Care for Prevention of Venous Thrombosis in Paediatric Acute Lymphoblastic Leukaemia (ALL)—Rationale and DesignThrombosis and Haemostasis, 2019
- Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolismResearch and Practice in Thrombosis and Haemostasis, 2018
- Andexanet Alfa for the Reversal of Factor Xa Inhibitor ActivityNew England Journal of Medicine, 2015